Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Caldan Therapeutics collaborates with Sygnature Discovery

Caldan Therapeutics announces that it has entered into integrated drug discovery collaboration with Sygnature Discovery Limited (Nottingham, UK). Sygnature will provide medicinal chemistry, computational sciences and informatics, bioscience and DMPK resource and intellectual input to complement Caldan’s existing capabilities and Type 2 Diabetes expertise.

Click here to view Caldan’s press release in full.

Latest News

View All

Sygnature Discovery wins Medilink Outstanding Achievement Award

Sygnature Discovery expands DMPK capabilities with acquisition…

Sygnature and RenaSci strengthen drug abuse leadership…

Sygnature Discovery boosts senior management team with…

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.